DUBLIN–(BUSINESS WIRE)–Feb 4, 2021–
The "Global Antibiotics Partnering Terms and Agreements 2010 to 2020" report has been added to ResearchAndMarkets.com’s offering.
The Global Antibiotics Partnering Terms and Agreements 2010 to 2020 report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains over 300 links to online copies of actual antibiotics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
Report scope
Global Antibiotics Partnering Terms and Agreements 2010 to 2020 includes:
- Trends in antibiotics dealmaking in the biopharma industry since 2010
- Analysis of antibiotics deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life antibiotics deals
- Access to over 300 antibiotics deal records and contract documents where available
- The leading antibody deals by value since 2010
- Most active antibiotics dealmakers since 2010
- The leading antibiotics partnering resources
In Global Antibiotics Partnering Terms and Agreements 2010 to 2020, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy and technology target
This report provides details of the latest antibiotics agreements announced in the healthcare sectors, covering:
- Antibiotics
- Aminoglycosides
- Cephalosporin
- Clindamycin
- Macrolides
- Penicillin
- Quinolones
- Sulfonamides
- Tetracycline
Key Topics Covered:
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in antibiotics dealmaking
2.1. Introduction
2.2. Antibiotics partnering over the years
2.3. Most active antibiotics dealmakers
2.4. Antibiotics partnering by deal type
2.5. Antibiotics partnering by therapy area
2.6. Antibiotics partnering by industry sector
2.7. Deal terms for antibiotics partnering
2.7.1 Antibiotics partnering headline values
2.7.2 Antibiotics deal upfront payments
2.7.3 Antibiotics deal milestone payments
2.7.4 Antibiotics royalty rates
2.8. The anatomy of an antibiotics deal
2.8. a. Case study 1: RRD International & Dipexium Pharmaceuticals
2.8.b. Case study 2: Hospira & Cempra Pharmaceutical
2.8.c. Case study 3: Astellas & Optimer Pharmaceuticals
Chapter 3 – Leading antibiotics deals
3.1. Introduction
3.2. Top antibiotics deals by value
Chapter 4 – Most active antibiotics dealmakers
4.1. Introduction
4.2. Most active antibiotics dealmakers
4.3. Most active antibiotics partnering company profiles
Chapter 5 – Antibiotics contracts dealmaking directory
5.1. Introduction
5.2. Antibiotics contracts dealmaking directory
Chapter 6 – Antibiotics dealmaking by technology type
- Antibiotics
- Aminoglycosides
- Cephalosporin
- Clindamycin
- Macrolides
- Metronidazole
- Penicillin
- Quinolones
- Tetracycline
Chapter 7 – Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
For more information about this report visit https://www.researchandmarkets.com/r/i1wtx9
View source version on businesswire.com:https://www.businesswire.com/news/home/20210204005800/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected] For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2021.
PUB: 02/04/2021 11:01 AM/DISC: 02/04/2021 11:01 AM
http://www.businesswire.com/news/home/20210204005800/en
